Morgan Stanley Reiterates Equal-Weight on Ascendis Pharma, Maintains $109 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $109 price target.
June 26, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma and maintained a $109 price target.
The news of Morgan Stanley reiterating an Equal-Weight rating on Ascendis Pharma and maintaining a $109 price target is neutral for the stock price in the short term. The rating suggests that the stock is fairly valued and the price target is in line with the current market price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100